Cargando…
Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
Background: The β-Lactam Infusion Group (BLING) III study is a prospective, multicentre, open, phase 3 randomised controlled trial comparing continuous infusion with intermittent infusion of β-lactam antibiotics in 7000 critically ill patients with sepsis. Objective: To describe a statistical analys...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692542/ https://www.ncbi.nlm.nih.gov/pubmed/38046078 http://dx.doi.org/10.51893/2021.3.OA4 |
_version_ | 1785152964946558976 |
---|---|
author | Billot, Laurent Lipman, Jeffrey Brett, Stephen J. De Waele, Jan J. Cotta, Menino Osbert Davis, Joshua S. Finfer, Simon Hammond, Naomi E. Knowles, Serena McGuinness, Shay Myburgh, John Paterson, David L. Peake, Sandra Rajbhandari, Dorrilyn Rhodes, Andrew Roberts, Jason A. Roger, Claire Shirwadkar, Charudatt Starr, Therese Taylor, Colman Dulhunty, Joel M. |
author_facet | Billot, Laurent Lipman, Jeffrey Brett, Stephen J. De Waele, Jan J. Cotta, Menino Osbert Davis, Joshua S. Finfer, Simon Hammond, Naomi E. Knowles, Serena McGuinness, Shay Myburgh, John Paterson, David L. Peake, Sandra Rajbhandari, Dorrilyn Rhodes, Andrew Roberts, Jason A. Roger, Claire Shirwadkar, Charudatt Starr, Therese Taylor, Colman Dulhunty, Joel M. |
author_sort | Billot, Laurent |
collection | PubMed |
description | Background: The β-Lactam Infusion Group (BLING) III study is a prospective, multicentre, open, phase 3 randomised controlled trial comparing continuous infusion with intermittent infusion of β-lactam antibiotics in 7000 critically ill patients with sepsis. Objective: To describe a statistical analysis plan for the BLING III study. Methods: The statistical analysis plan was designed by the trial statistician and chief investigators and approved by the BLING III management committee before the completion of data collection. Statistical analyses for primary, secondary and tertiary outcomes and planned subgroup analyses are described in detail. Interim analysis by the Data Safety and Monitoring Committee (DSMC) has been conducted in accordance with a pre-specified DSMC charter. Results and conclusions: The statistical analysis plan for the BLING III study is published before completion of data collection and unblinding to minimise analysis bias and facilitate public access and transparent analysis and reporting of study findings. Trial registration:ClinicalTrials.gov Registry NCT03212990. |
format | Online Article Text |
id | pubmed-10692542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106925422023-12-03 Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis Billot, Laurent Lipman, Jeffrey Brett, Stephen J. De Waele, Jan J. Cotta, Menino Osbert Davis, Joshua S. Finfer, Simon Hammond, Naomi E. Knowles, Serena McGuinness, Shay Myburgh, John Paterson, David L. Peake, Sandra Rajbhandari, Dorrilyn Rhodes, Andrew Roberts, Jason A. Roger, Claire Shirwadkar, Charudatt Starr, Therese Taylor, Colman Dulhunty, Joel M. Crit Care Resusc Original Article Background: The β-Lactam Infusion Group (BLING) III study is a prospective, multicentre, open, phase 3 randomised controlled trial comparing continuous infusion with intermittent infusion of β-lactam antibiotics in 7000 critically ill patients with sepsis. Objective: To describe a statistical analysis plan for the BLING III study. Methods: The statistical analysis plan was designed by the trial statistician and chief investigators and approved by the BLING III management committee before the completion of data collection. Statistical analyses for primary, secondary and tertiary outcomes and planned subgroup analyses are described in detail. Interim analysis by the Data Safety and Monitoring Committee (DSMC) has been conducted in accordance with a pre-specified DSMC charter. Results and conclusions: The statistical analysis plan for the BLING III study is published before completion of data collection and unblinding to minimise analysis bias and facilitate public access and transparent analysis and reporting of study findings. Trial registration:ClinicalTrials.gov Registry NCT03212990. Elsevier 2023-10-18 /pmc/articles/PMC10692542/ /pubmed/38046078 http://dx.doi.org/10.51893/2021.3.OA4 Text en © 2021 College of Intensive Care Medicine of Australia and New Zealand. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Billot, Laurent Lipman, Jeffrey Brett, Stephen J. De Waele, Jan J. Cotta, Menino Osbert Davis, Joshua S. Finfer, Simon Hammond, Naomi E. Knowles, Serena McGuinness, Shay Myburgh, John Paterson, David L. Peake, Sandra Rajbhandari, Dorrilyn Rhodes, Andrew Roberts, Jason A. Roger, Claire Shirwadkar, Charudatt Starr, Therese Taylor, Colman Dulhunty, Joel M. Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis |
title | Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis |
title_full | Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis |
title_fullStr | Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis |
title_full_unstemmed | Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis |
title_short | Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis |
title_sort | statistical analysis plan for the bling iii study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692542/ https://www.ncbi.nlm.nih.gov/pubmed/38046078 http://dx.doi.org/10.51893/2021.3.OA4 |
work_keys_str_mv | AT billotlaurent statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT lipmanjeffrey statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT brettstephenj statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT dewaelejanj statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT cottameninoosbert statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT davisjoshuas statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT finfersimon statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT hammondnaomie statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT knowlesserena statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT mcguinnessshay statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT myburghjohn statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT patersondavidl statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT peakesandra statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT rajbhandaridorrilyn statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT rhodesandrew statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT robertsjasona statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT rogerclaire statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT shirwadkarcharudatt statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT starrtherese statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT taylorcolman statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT dulhuntyjoelm statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis AT statisticalanalysisplanfortheblingiiistudyaphase3multicentrerandomisedcontrolledtrialofcontinuousversusintermittentblactamantibioticinfusionincriticallyillpatientswithsepsis |